Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-11-02
2010-02-16
Steadman, David J (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S380000, C514S002600, C514S008100, C514S012200, C514S843000, C424S094640
Reexamination Certificate
active
07662923
ABSTRACT:
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
REFERENCES:
patent: 4784950 (1988-11-01), Hagen et al.
patent: 4904584 (1990-02-01), Shaw
patent: 5009889 (1991-04-01), Taylor, Jr. et al.
patent: 5041376 (1991-08-01), Gething et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5180583 (1993-01-01), Hedner
patent: 5225537 (1993-07-01), Foster
patent: 5258288 (1993-11-01), Wydro et al.
patent: 5288629 (1994-02-01), Berkner
patent: 5374617 (1994-12-01), Morrissey et al.
patent: 5460950 (1995-10-01), Barr et al.
patent: 5504064 (1996-04-01), Morrissey et al.
patent: 5516640 (1996-05-01), Watanabe et al.
patent: 5580560 (1996-12-01), Nicolaisen et al.
patent: 5648254 (1997-07-01), Mulvihill et al.
patent: 5788965 (1998-08-01), Berkner et al.
patent: 5817788 (1998-10-01), Berkner et al.
patent: 5824639 (1998-10-01), Berkner
patent: 5833982 (1998-11-01), Berkner et al.
patent: 5837843 (1998-11-01), Smirnov et al.
patent: 5847085 (1998-12-01), Esmon et al.
patent: 5861374 (1999-01-01), Berkner et al.
patent: 5891843 (1999-04-01), Turecek et al.
patent: 5965425 (1999-10-01), Barr et al.
patent: 5986079 (1999-11-01), Barr et al.
patent: 6013620 (2000-01-01), Turecek et al.
patent: 6017882 (2000-01-01), Nelsestuen
patent: 6071514 (2000-06-01), Grinnell et al.
patent: 6423826 (2002-07-01), Nelsestuen et al.
patent: 6693075 (2004-02-01), Nelsestuen
patent: 6747003 (2004-06-01), Nelsestuen
patent: 6762286 (2004-07-01), Nelsestuen
patent: 6806063 (2004-10-01), Pedersen et al.
patent: 6903069 (2005-06-01), Pingel et al.
patent: 2003/0100506 (2003-05-01), Nelsestuen
patent: 2003/0100740 (2003-05-01), Persson et al.
patent: 2003/0104978 (2003-06-01), Persson et al.
patent: 2003/0211094 (2003-11-01), Nelsestuen
patent: 2003/0211460 (2003-11-01), Nelsestuen
patent: 0 296 413 (1988-12-01), None
patent: 0 354 504 (1990-02-01), None
patent: 0 512 011 (1992-11-01), None
patent: 64-085096 (1989-03-01), None
patent: WO 88/10295 (1988-12-01), None
patent: WO 91/11514 (1991-08-01), None
patent: WO 92/15686 (1992-09-01), None
patent: WO 94/27631 (1994-12-01), None
patent: WO 96/00577 (1996-01-01), None
patent: WO 99/03498 (1999-01-01), None
patent: WO 99/20767 (1999-04-01), None
patent: WO 99/66031 (1999-12-01), None
patent: WO 00/28065 (2000-05-01), None
patent: WO 00/54787 (2000-09-01), None
patent: WO 00/66753 (2000-11-01), None
patent: WO 01/58935 (2001-08-01), None
patent: WO 01/83725 (2001-11-01), None
patent: WO 02/02764 (2002-01-01), None
patent: WO 02/03075 (2002-01-01), None
patent: WO 02/22776 (2002-03-01), None
patent: WO 02/29025 (2002-04-01), None
patent: WO 02/38162 (2002-05-01), None
patent: WO02/070681 (2002-09-01), None
patent: WO 02/077218 (2002-10-01), None
patent: WO 03/027147 (2003-04-01), None
patent: WO 03/037932 (2003-05-01), None
patent: WO 03/055512 (2003-07-01), None
patent: WO 03/093465 (2003-11-01), None
patent: WO 2004/029091 (2004-04-01), None
patent: WO 2004/083361 (2004-09-01), None
Harvey, “Mutagenesis of the γ-Carboxyglutamic Acid Domain of Human Factor VII to Generate Maximum Enhancement of the Membrane Contact Site,”J. Biol. Chem., 2003, 278:8363-8369.
Henderson et al., “Response of Factor VIII and IX-Deficient Blood to Wild Type and High Membrane Affinity Mutant Factor VIIa in an In Vitro Whole Blood Clotting Assay: Possible Correlation to Clinical Outcome,”Thromb. Haemost., 2002, 88:98-103.
Stone, “Unusual Benefits of Macromolecular Shielding by Polyethylene Glycol for Reactions at the Diffusional Limit: The Case of Factor VIIai and Tissue Factor,”Biochem., 2002, 41:15820-15825.
Arnljots et al., “Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa,”J. Vasc. Surg., 1997, 25:341-346.
Bauer, “Treatment of Factor VII Deficiency with Recombinatn Factor VIIa,”Haemostasis, 1996, 26(Suppl. 1):155-158.
Bodner et al., “The Pituitary-Specific Transcription Factor GHF-1 Is a Homeobox-Containing Protein,”Cell, 1988, 55:505-518.
Bradford, “A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding,”Analyt. Biochem., 1976, 72:248-254.
Broze et al., “Monoclonal Anti-human Factor VII Antibodies,”J. Clin. Invest., 1985, 76:937-946.
Cheung and Stafford, “Localization of an Epitope of a Calcium-Dependent Monoclonal Antibody fo the N-Terminal Region of the GLA Domain of Human Factor VII,”Thromb. Res., 1995, 79(2):199-206.
Choudhri et al., “Targeted Inhibition of lntrinsic Coagulation Limits Cerebral Injury in Stroke without Increasing Intracerebral Hemorrhage,”J. Exp. Med., 1999, 190(1):91-99.
Christiansen et al., “Hydrophobic Amino Acid Residues of Human Anticoagulation Protein C That Contribute to Its Functional Binding to Phospholipid Vesicles,”Biochemistry, 1995, 34:10376-10382.
Dackiw et al., “Prevention of Endotoxin-Induced Mortality by Antitissue Factor Immunization,”Arch. Surg., 1996, 131:1273-1278.
Dahlbäck, “Inherited Thrombophilia: Resistance to Activated Protein C as a Pathogenic Factor of Venous Thromboembolism,”Blood, 1995, 85(3):607-614.
Dickinson and Ruf, “Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tissue Factor,”J. Biol. Chem., 1997, 272(32):19875-19879.
Esmon et al., “Isolation of a Membrane-bound Cofactor for Thrombin-catalyzed Activation of Protein C,”J. Biol. Chem., 1982, 257(2):859-864.
Evans and Nelsestuen, “Inportance ofcis-Proline 22 in the Membrane-Binding Conformation of Bovine Prothrombin,”Biochemistry, 1996, 35:8210-8215.
Evans and Nelsestuen, “How Important Are Proline 22 and the 41-45 Helical Stack to Membrane Binding by Bovine Prothrombin?”Protein Sci., 1996, 5(Suppl. 1):163, Abstract No. 606-S.
Felgner et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,”Proc. Natl. Acad. Sci. USA, 1987, 84:7413-7417.
Fiore et al., “The Biochemical Basis for the Apparent Defect of Soluble Mutant Tissue Factor in Enhancing the Proteolytic Activities of Factor VIIa,”J. Biol. Chem., 1994, 269(1):143-149.
Freedman et al., “Identification of the Phospholipid Binding Site in the Vitamin K-dependent Blood Coagulation Protein Factor IX,”J. Biol. Chem., 1996, 271(27):16227-16236.
Han et al., “Isolation of a protein Z-dependent plasma protease inhibitor,”Proc. Natl. Acad. Sci. USA, 1998, 95:9250-9255.
He et al., “Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein-S-defining modules important for the species specificity of the activated protein C cofactor activity,”Eur. J. Biochem., 1995, 227:433-440.
Hedner et al., “Recombinant Activated Factor VII in the Treatment of Bleeding Episodes in Patients With Inherited and Acquired Bleeding Disorders,”Transfusion Medicine Reviews, 1993, VII(2):78-83.
Hope et al., “Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane protential,”Biochim. Biophys. Acta, 1985, 812:55-65.
Hoskins et al., “Cloning and characterization of human liver cDNA encoding a protein S precursor,”Proc. Natl. Acad. Sci. USA, 1987, 84:349-353.
Huang, “Studies on Phosphatidylcholine Vesicles, Formation and Physical Characteristics,”Biochemistry, 1969, 8:344-352.
Humphries et al., “Chemical methods of protein synthesis and modification,”Curr. Opin. Biotechnol., 1991, 2:539-543.
Jurlander et al., “Recombinant Activated Factor VII (rFVIIa): Characterization, Manufacturing, and Clinical Development,”Semin. Thromb. Hemos.,
Fish & Richardson P.C.
Regents of the University of Minnesota
Steadman David J
Tsay Marsha M
LandOfFree
Modified vitamin K-dependent polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified vitamin K-dependent polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified vitamin K-dependent polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4210231